- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
A Lixiana (edoxaban) print journal ad was cleared on imagery and dosing allegations, but breached the Code for failing to signpost that…
Otsuka Europe admitted it missed SOP timelines to notify affiliates of a Samsca SPC update and delayed updated prescribing information. PMCPA ruled…
Eliquis HCP site banner ‘Choose Eliquis’ was not misleading, but the adverse event reporting statement wasn’t included within the promotional pages themselves—breach…
Employee complaint: pressure to boost activity led to guidance to log emails as calls, unclear call vs contact briefings, HCP prep work…
LEO made a voluntary admission after five 2020 transfers of value (4 HCP, 1 HCO) were omitted from its UK Disclosure UK…
PMCPA found multiple breaches on LEO’s Kyntheum HCP website, including misleading/exaggerated claims and unbalanced safety messaging (Clause 2 at several points). Appeals…
PMCPA found Daiichi Sankyo’s Lixiana HCP mobile homepage made prescribing info and AE reporting insufficiently prominent by placing them behind an expandable…
Polivy dosing webpage gave the impression it contained all key administration info, but omitted SPC instructions on a dedicated infusion line/filter and…
Novartis’ HCP website claim “THINK Symptom-free” for Xolair in CSU was ruled misleading and unsubstantiated (Clauses 6.1, 6.2, 5.1). Other claims (“UNLOCK…
Ex-employee alleged CSL Vifor’s non-promotional NHS service was targeted to Ferinject-using hospitals and amounted to disguised promotion/inducement. Panel found allegations not evidenced…
Astellas self-reported undisclosed transfers of value to two healthcare organisations and five patient organisations (2019–2021). PMCPA found multiple disclosure breaches and a…
A naloxone awareness poster on a telephone booth linked to a website showing branded naloxone products. PMCPA ruled it advertised a POM…
PMCPA found Janssen breached Clauses 5.1 and 6.1 (x3) over a PAH symposium video: relative risk shown without absolute risk, ARR mislabelled,…
Ex-employee alleged Otsuka withheld relevant facts and used unsigned witness statements in a 2015 PMCPA case response. Panel found breaches of Clauses…
Five weight-loss media articles were complained about. Novo Nordisk was not responsible for four. One Sunday Times interview quote was ruled promotional…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.